Pharmaceutical

Bausch + Lomb doubles production at Macherio

The American multinational will invest €28 million in its production site in Lombardy. Global CEO Saunders said: “Italia has an investment-friendly environment; we will create new jobs.”

by Cristina Casadei

4' min read

Translated by AI
Versione italiana

4' min read

Translated by AI
Versione italiana

“See-3PO is an opportunity that will allow our people to focus more on higher-value-added activities,” says the global president and CEO of Bausch + Lomb, Brent Saunders, immediately after shaking hands with the humanoid robot that will be joining the group through the gates of the Macherio site (Monza Brianza).

Here yesterday, Saunders announced a major investment to double production and met with staff at a town hall meeting. The global meeting, held for the first time at a production site, also provided an opportunity for 3,000 of the American multinational’s 13,000 workers to decide on the name of their new ‘colleague’, taking inspiration from the Star Wars android.

Loading...

“In Macherio,” says the American manager, “we found a very favourable environment for investment, thanks to the high level of technical expertise, manufacturing excellence and a strong culture of innovation, as well as the support of local politicians and a network of links with schools and universities.”

We will be investing $33 million – over €28 million – in the expansion of the site, in addition to the $10 million – over €8.6 million – already invested over the last five years. Further investments are planned by 2031, which will significantly boost Italia’s economic impact. As if to reassure us about the compatibility between AI, humanoids and human labour, Saunders explains that this investment ‘will boost employment: we will create 50 new jobs, representing an increase of almost 50% in the site’s workforce, which currently stands at 100. If we also take into account the wider economic impact, the number of new jobs will rise to 100.”

Brent Saunders, Headshot

Within the global operations of the American multinational, based in Bridgewater, New Jersey, which manufactures products that help people see better – ranging from sterile solutions for contact lens care to eye care products such as artificial tears – Italia plays an increasingly strategic role: ‘It has long been an important part of Bausch + Lomb’s global presence. Our ongoing investments reflect our confidence not only in the talent and capabilities of the region, but also in the crucial role that Italia will continue to play in helping us serve patients and customers around the world,’ says Saunders.

‘Macherio is on a long-term growth trajectory and will evolve from a site serving Europe to one serving the whole world, thereby strengthening our global supply chain and accelerating innovation thanks to the new research and development laboratories that will be opened here.’

“The unique feature of the site is that it has been designed ‘to provide advanced sterile production facilities with areas compliant with EU Annex 1 standards, featuring three new sterile filling lines for products ranging from 10 ml to 500 ml’,” explains Vincenzo Abruscato, President and CEO for Italia. It will also have significant research and development capacity, with chemical and biological laboratories and a pilot line for technology transfer and new product development. On the production front, the investment will enable a doubling of output, bringing annual production to 60 million vials by 2030, up from the current 30 million.”

Vincenzo Abruscato

The global multinational has a turnover of €5 billion and 13,000 employees. It operates in 100 countries and manufactures 400 products at 23 production sites across 10 countries, including the site in Macherio, Italia, where it has been based since 1972.

‘In Italy, the company employs 250 people across its headquarters in Vimodrone and its site in Macherio, and generates a turnover of $140 million – or €127 million – which is growing steadily: between 2021 and 2025, turnover has increased by 41%, and just five years ago it was under 100 million euros,” says Abruscato, describing the growth trajectory of Italia, which is set to become an increasingly strategic hub for Bausch + Lomb, thanks above all to the expansion of the new site and the research and development laboratories that will also be increasingly established in Italy.

Globally, Bausch + Lomb embraces the open innovation approach and makes substantial investments in research and development, having spent $340 million in 2025. It currently has 60 projects in the pipeline, with over a thousand people working on them.

The expansion of the plant will generate over €18 million in turnover for Italian companies in both the construction sector and the machinery supply sector, all of which are Italian. “We are working in close collaboration not only with the local council, but also with the Ministry of Economic Development (MIMIT), which has confirmed its strategic interest in the project,” highlights Abruscato, “but this would not have been possible without the support and vision of Macherio Council and Mayor Franco Radaelli.”

That is what it means to have deep roots in a community. The factory, after all, is deeply rooted in the local community. During the COVID-19 pandemic, employees donated their meal allowances to raise funds for San Gerardo Hospital in Monza, to which was added a further contribution from the Bausch Foundation».

Copyright reserved ©
Loading...

Brand connect

Loading...

Newsletter

Notizie e approfondimenti sugli avvenimenti politici, economici e finanziari.

Iscriviti